Hispolon inhibits RANKL induced osteoclast differentiation in vitro

Immunol Lett. 2021 Mar:231:35-42. doi: 10.1016/j.imlet.2021.01.003. Epub 2021 Jan 8.

Abstract

Hispolon (HISP) is a bioactive compound isolated from Phellinu linteus. It has various pharmacological activities, including antioxidant, anti-inflammatory, and anti-cancer. However, its anti-osteoclastogenic activity has not yet been reported. Hence, in the current study, we have explored the anti-osteoclastogenic activity of HISP and elucidated the molecular mechanisms. HISP inhibited the RANKL induced differentiation of RAW 264.7 cells into osteoclasts in a dose-dependent manner. Mechanistic studies showed that HISP inhibited RANKL-mediated activation of NF-κB and MAPK signaling pathways in osteoclast precursors RAW 264.7 cells. In addition, Hispolon also downregulated the expression of master transcriptional factors essential for osteoclast differentiation, such as NFATc1 and c-FOS. In conclusion, these findings establish molecular mechanisms behind the anti-osteoclastogenic activity of HISP.

Keywords: Bone resorption; Hispolon; Osteoclastogenesis; RANKL; RAW264.7.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Actins / metabolism
  • Animals
  • Biomarkers
  • Catechols / chemistry
  • Catechols / pharmacology*
  • Cell Differentiation / drug effects*
  • Cell Survival / drug effects
  • Cells, Cultured
  • Fluorescent Antibody Technique
  • MAP Kinase Signaling System
  • Mice
  • Osteoclasts / cytology*
  • Osteoclasts / drug effects*
  • Osteoclasts / metabolism*
  • Osteogenesis
  • RANK Ligand / metabolism*
  • RAW 264.7 Cells
  • Reactive Oxygen Species / metabolism

Substances

  • Actins
  • Biomarkers
  • Catechols
  • RANK Ligand
  • Reactive Oxygen Species
  • Tnfsf11 protein, mouse
  • hispolon